You are here: Home: Audio Program Guide: BCU 5 | 2007 Audio: BCU 5 | 2007
 
  Go to interview with Sharon Giordano, MD, MPH
Go to interview with Rowan T Chlebowski, MD, PhD
Go to Tumor Panel Case Discussion
Go to interview with Jack Cuzick, PhD
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Giordano, MD Sharon Giordano, MD, MPH
Assistant Professor of Medicine
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas


  
  Click here to download the entire interview  
Track 1 Congestive heart failure in older women treated with anthracyclines: Analysis of SEER-Medicare data
Track 2 Acute myeloid leukemia (AML) in older women after adjuvant breast cancer therapy: Analysis of SEER-Medicare data
Track 3 Independent predictors of risk for cardiovascular events
Track 4 Use of the Oncotype DX™ assay in treatment decision-making
Track 5 Use of adjuvant docetaxel/carboplatin/trastuzumab (TCH)
Track 6 Cardiotoxicity associated with newer agents targeting the HER2 family of receptors

Track 7 Incidence and outcome of male breast cancer
Track 8 Adjuvant hormonal therapy for male breast cancer
Track 9 Psychosocial issues in male breast cancer
Track 10 Adjuvant chemotherapy for male breast cancer
Track 11 Radiation exposure as a risk factor in male breast cancer
Track 12 Trends in survival of Stage IV breast cancer among Caucasian and African American patients
Track 13 Heterogeneity in the long-term survival of metastatic breast cancer
Track 14 Incorporation of bevacizumab into the management of metastatic breast cancer
Track 15 Treatment of hormone receptor-positive metastatic breast cancer
Track 16 Monthly versus every three-month LHRH agonist injections
Track 17 Initial and extended adjuvant hormonal therapy for postmenopausal patients
Track 18 Research contributions from large national databases
Track 19 Bisphosphonate use and osteonecrosis of the jaw
Track 20 Cognitive dysfunction in patients undergoing cancer treatment
     
Chebowski, MD Rowan T Chlebowski, MD, PhD
Professor of Medicine
David Geffen School of Medicine at UCLA
Chief, Medical Oncology
Harbor-UCLA Medical Center
Torrance, California
  
  Click here to download the entire interview  
Track 1 Decrease in breast cancer incidence in the United States in 2003
Track 2 Changes in menopausal hormone replacement as a potential contributor to decline in breast cancer incidence
Track 3 Influence of hormones on the development of breast cancer
Track 4 Reduction in the incidence of iatrogenic breast cancer
Track 5 Women’s Health Initiative (WHI) dietary modification trial and risk of breast and colorectal cancer
Track 6 Treatment of preclinical disease and prevention of carcinogenesis

Track 7 Safety of estrogen alone as menopausal hormone replacement
Track 8 Statin use and breast cancer: Prospective results from the WHI
Track 9 Women’s Intervention Nutrition Study (WINS): Dietary fat reduction and breast cancer outcome
Track 10 NCI Canada study of reduced caloric intake and increased physical activity in patients with hormone receptor-positive tumors
Track 11 Reactions to the WINS data
Track 12 Potential research opportunities to evaluate lifestyle modifications
Track 13 Long natural history of hormone receptor-positive early breast cancer
audio
Track 14 Efficacy results of up-front aromatase inhibitors (AIs) in ATAC and BIG 1-98
audio
Track 15 Potential differences in cardiovascular adverse effects among AIs
audio
Track 16 Adjuvant AIs and bone health
audio
Track 17 Adjuvant AIs and bisphosphonates
audio
Track 18 Effect of anastrozole on bone mineral density: Five-year results of ATAC
audio
Track 19 Use of screening and bisphosphonates in women receiving adjuvant AIs
audio
     
Tumor Panel Case Discussion
       
Chebowski, MD Rowan T Chlebowski, MD, PhD
Professor of Medicine
David Geffen School of Medicine
at UCLA; Chief, Medical Oncology
Harbor-UCLA Medical Center
Torrance, California
 Jahanzeb, MD Mohammad Jahanzeb, MD
Van Vleet Endowed Professor in Medical Oncology
Chief, Division of Hematology Oncology
Fellowship Program Director
University of Tennessee
Health Science Center
Memphis, Tennessee
       
Dickler, MD Maura N Dickler, MD
Assistant Attending Physician
Breast Cancer Medicine Service
Memorial Sloan-Kettering
Cancer Center
New York, New York		    
Click here to download the entire case discussion  
Track 1 Case discussion: A 60-year-old woman with a 2.1-cm, intermediate-grade, hormone receptor-positive, HER2-negative, node-positive tumor who received five years of an AI
Track 2 Clinical management of patients completing five years of an adjuvant AI
Track 3 Potential clinical implications of sequencing AIs and tamoxifen in BIG 1-98
Track 4 Case discussion: A 64-year-old woman with a 2.5-cm, hormone receptor-positive, HER2- negative, node-positive (10/12) tumor with a history of cardiac disease
Track 5 Treatment decision-making for a woman with high-risk breast cancer and cardiac comorbidities
Track 6 Adjuvant docetaxel/cyclophosphamide (TC)

Track 7 Nanoparticle albumin-bound (nab) paclitaxel
Track 8 Tolerability and side effects of TC compared to AC
Track 9 Case discussion: A 44-year-old woman with multiple hepatic metastases after treatment for hormone receptor-positive, HER2-negative, node-negative invasive lobular carcinoma
Track 10 First-line therapy for an asymptomatic, treatment-naïve, premenopausal patient with hormone receptor-positive disease
Track 11 Algorithm for sequential hormonal therapy in a premenopausal patient with metastatic disease
audio
Track 12 Capecitabine/bevacizumab as part of a clinical trial in a patient rapidly progressing on hormonal therapy after first-line doxorubicin/docetaxel
audio
Track 13 Four-year response to capecitabine/bevacizumab as part of a clinical trial
audio
Track 14 Case discussion: A 52-year-old woman with a 2-cm, intermediate-grade, hormone receptor-positive, HER2-negative, node-positive tumor who completed TAC and three years of tamoxifen
audio
Track 15 Use of hormone levels to guide switching from tamoxifen to an AI
audio
Track 16 Effectiveness of adjuvant LHRH agonists in suppressing ovarian function
audio
Track 17 Case discussion: A 53-year-old woman with a 4-cm, Grade III, triple-negative, node-negative early breast tumor
audio
Track 18 Feasibility study of dose-dense AC/nab paclitaxel with bevacizumab
audio
Track 19 Incidence of triple-negative breast cancer in African Americans
audio
Track 20 Treatment approaches for women with triple-negative early breast cancer
audio
Track 21 CAN-NCIC-MA21: CEF versus dose-dense EC arrow paclitaxel versus AC arrow paclitaxel in node-positive or high-risk, node-negative breast cancer
audio
Track 22 Case discussion: A 40-year-old premenopausal woman with hormone receptor-positive, HER2- positive, inflammatory breast cancer with lymph node, bone and lung metastases
Track 23 Selection of a chemotherapy regimen in combination with trastuzumab as first-line therapy
Track 24 Treatment with nab paclitaxel/carboplatin with trastuzumab in a Phase II study
Track 25 First-line treatment with bevacizumab/trastuzumab for patients with HER2-positive disease

     
Cuzick, MD Jack Cuzick, PhD
John Snow Professor of Epidemiology
Cancer Research UK Centre for Epidemiology, Mathematics and Statistics
Wolfson Institute of Preventive Medicine
Queen Mary’s School of Medicine and Dentistry
University of London
London, United Kingdom
  
  Click here to download the entire interview  
Track 1 Meta-analysis of LHRH agonists as adjuvant therapy for premenopausal patients with hormone receptor-positive disease
Track 2 Clinical benefits of adjuvant ovarian ablation/suppression
Track 3 Monthly versus every three-month LHRH agonist therapy
Track 4 Adjuvant ovarian suppression with AI therapy for premenopausal patients
Track 5 Impact of 2D6 metabolism on tamoxifen therapy
Track 6 Modeling the optimal adjuvant endocrine therapy strategy for postmenopausal patients

Track 7 Predictive role of HER2 and PR in hormone receptor-positive breast cancer
Track 8 Up-front adjuvant AI therapy versus tamoxifen for postmenopausal patients
Track 9 Adjuvant AIs and bone health
Track 10 Duration of adjuvant AI therapy
Track 11 ATLAS and aTTom trials of longer-term adjuvant tamoxifen
audio
Track 12 Adjuvant AIs and risk of cardiovascular disease
audio
Track 13 Clinical trials evaluating anastrozole in the treatment of postmenopausal patients with DCIS
audio
Track 14 Evaluation of sequencing letrozole and tamoxifen in BIG 1-98
audio
Track 15 Extended carryover benefit with tamoxifen in the IBIS-1 chemoprevention study
audio
Track 16 IBIS-2 chemoprevention study comparing anastrozole to placebo
audio
Track 17 AIs and arthralgias